norfloxacin has been researched along with Pyelonephritis in 12 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Pyelonephritis: Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred thirty-eight patients with pyelonephritis were treated with norfloxacin, 400 mg twice daily." | 9.06 | Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection. ( Corrado, ML; Lancaster, MS; Roylance, PJ; Struble, WE, 1990) |
| "In a coordinated, double-blind multi-centre trial, adults with symptoms of acute pyelonephritis were randomly assigned to receive a two-week course of oral treatment with either 400 mg norfloxacin twice daily or 1 g cefadroxil twice daily." | 9.06 | Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. ( Englund, G; Lincoln, K; Nilsson, LG; Sandberg, T, 1990) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 9.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "The clinical effectiveness and safety of norfloxacin were evaluated in 34 patients with urinary tract infections." | 7.67 | [Clinical studies of norfloxacin in urinary tract infections]. ( Kurita, T; Matsuura, T, 1985) |
| "One hundred thirty-eight patients with pyelonephritis were treated with norfloxacin, 400 mg twice daily." | 5.06 | Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection. ( Corrado, ML; Lancaster, MS; Roylance, PJ; Struble, WE, 1990) |
| "In a coordinated, double-blind multi-centre trial, adults with symptoms of acute pyelonephritis were randomly assigned to receive a two-week course of oral treatment with either 400 mg norfloxacin twice daily or 1 g cefadroxil twice daily." | 5.06 | Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. ( Englund, G; Lincoln, K; Nilsson, LG; Sandberg, T, 1990) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 5.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "To investigate the cost-effectiveness of two outpatient treatment strategies, TMP-SMX and norfloxacin, for acute uncomplicated pyelonephritis in adult women between the ages of 18 and 65 years." | 3.72 | A cost-effectiveness analysis of treatment strategies for acute uncomplicated pyelonephritis in women. ( Chen, SC; Chen, WJ; Davis, MA; Yen, ZS, 2003) |
| "The clinical effectiveness and safety of norfloxacin were evaluated in 34 patients with urinary tract infections." | 3.67 | [Clinical studies of norfloxacin in urinary tract infections]. ( Kurita, T; Matsuura, T, 1985) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cattrall, JWS | 1 |
| Robinson, AV | 1 |
| Kirby, A | 1 |
| Yen, ZS | 1 |
| Davis, MA | 1 |
| Chen, SC | 1 |
| Chen, WJ | 1 |
| Caron, F | 1 |
| Cronberg, S | 1 |
| Banke, S | 1 |
| Bergman, B | 1 |
| Boman, H | 1 |
| Eilard, T | 1 |
| Elbel, E | 1 |
| Hugo-Persson, M | 1 |
| Johansson, E | 1 |
| Kuylenstierna, N | 1 |
| Lanbeck, P | 1 |
| Lindblom, A | 1 |
| Paulsen, O | 1 |
| Schönbeck, C | 1 |
| Walder, M | 1 |
| Wieslander, P | 1 |
| Hyslop, DL | 1 |
| Bischoff, W | 1 |
| Corrado, ML | 1 |
| Roylance, PJ | 1 |
| Struble, WE | 1 |
| Lancaster, MS | 1 |
| Sandberg, T | 1 |
| Englund, G | 1 |
| Lincoln, K | 1 |
| Nilsson, LG | 1 |
| Puppo, P | 1 |
| Germinale, F | 1 |
| De Rose, AF | 1 |
| Iatrakis, G | 1 |
| Kourounis, G | 1 |
| Georgoulias, N | 1 |
| Filippidis, I | 1 |
| Louvrou, N | 1 |
| Deligianis, V | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Matsuura, T | 1 |
| Kurita, T | 1 |
2 reviews available for norfloxacin and Pyelonephritis
| Article | Year |
|---|---|
A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Drug Comb | 2018 |
[Current role of aminoglycosides in the treatment of acute pyelonephritis].
Topics: Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefadroxil | 1998 |
5 trials available for norfloxacin and Pyelonephritis
| Article | Year |
|---|---|
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftibut | 2001 |
Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cefaclor; Cephalosporins; Diarrhea; Double-Blind Method; | 1992 |
Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection.
Topics: Administration, Oral; Antibody-Coated Bacteria Test, Urinary; Clinical Trials as Topic; Cross Infect | 1990 |
Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Bacteriuria; Cefadroxil; Chi-Square Distr | 1990 |
[Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Aztreonam; Clinical Trials as Topic; Cystitis; F | 1989 |
5 other studies available for norfloxacin and Pyelonephritis
| Article | Year |
|---|---|
A cost-effectiveness analysis of treatment strategies for acute uncomplicated pyelonephritis in women.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cost- | 2003 |
[Treatment of urinary infections in pregnant women].
Topics: Ampicillin; Female; Humans; Norfloxacin; Pregnancy; Pregnancy Complications, Infectious; Pyelonephri | 1989 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
[Clinical studies of norfloxacin in urinary tract infections].
Topics: Adult; Aged; Cystitis; Drug Evaluation; Drug Resistance, Microbial; Enterobacteriaceae; Female; Huma | 1985 |